Cargando…
Valoctocogene roxaparvovec gene transfer in participants with HIV
Autores principales: | Ragni, Margaret V., Majerus, Elaine, Fong, Sylvia, Yates, Bridget, Scheeler, Stephen, Razon, Lisa, Yu, Hua, Reddy, Divya B., Robinson, Tara M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130610/ https://www.ncbi.nlm.nih.gov/pubmed/36696462 http://dx.doi.org/10.1182/bloodadvances.2022008948 |
Ejemplares similares
-
Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A
por: Pasi, K John, et al.
Publicado: (2021) -
Prednisolone Does Not Regulate Factor VIII Expression in Mice Receiving AAV5-hFVIII-SQ: Valoctocogene Roxaparvovec
por: Zhang, Lening, et al.
Publicado: (2019) -
Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A
por: Long, Brian R., et al.
Publicado: (2021) -
The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2021) -
Accelerator Operation at the GSI High Current Injector
por: Barth, W, et al.
Publicado: (2001)